Published in J Immunother on October 01, 2010
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell (2014) 5.87
The pancreas cancer microenvironment. Clin Cancer Res (2012) 4.10
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A (2013) 2.41
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat Med (2016) 2.27
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol (2016) 2.09
Fibroblast heterogeneity in the cancer wound. J Exp Med (2014) 2.09
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res (2014) 2.00
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst (2011) 1.86
T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma. Cancer Cell (2015) 1.71
Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res (2014) 1.62
Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterology (2013) 1.55
Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol (2015) 1.54
Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res (2014) 1.43
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene (2016) 1.39
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. Cancer Immunol Res (2015) 1.31
Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31
Potential targets for pancreatic cancer immunotherapeutics. Immunotherapy (2011) 1.29
Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity. Gut (2014) 1.23
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med (2015) 1.18
Immunotherapy for metastatic solid cancers. Adv Surg (2011) 1.16
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. Gastroenterology (2015) 1.12
Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07
Elements of cancer immunity and the cancer-immune set point. Nature (2017) 1.05
Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine. Med Sci Monit (2013) 1.03
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res (2013) 1.02
Tumor-stromal interactions in pancreatic cancer. Crit Rev Oncog (2013) 1.01
Stromal reengineering to treat pancreas cancer. Carcinogenesis (2014) 1.00
Immunotherapy updates in pancreatic cancer: are we there yet? Ther Adv Med Oncol (2013) 1.00
Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease. Oncologist (2012) 0.99
Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. Drug Des Devel Ther (2015) 0.97
Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res (2016) 0.96
Re-adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol Rev (2014) 0.94
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) (2014) 0.92
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol (2015) 0.91
Advances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockade. J Hematol Oncol (2015) 0.91
Vaccines for pancreatic cancer. Cancer J (2012) 0.90
Immunotherapy for gastrointestinal malignancies. Cancer Control (2013) 0.90
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. J Immunother Cancer (2016) 0.90
Optimum chemotherapy in the management of metastatic pancreatic cancer. World J Gastroenterol (2014) 0.90
Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. Oncoimmunology (2014) 0.89
Risk factors and therapeutic targets in pancreatic cancer. Front Oncol (2013) 0.88
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy. Clin Cancer Res (2013) 0.88
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist (2014) 0.87
Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. Genes Immun (2013) 0.87
Current advances in T-cell-based cancer immunotherapy. Immunotherapy (2014) 0.86
Tumour immunogenicity, antigen presentation and immunological barriers in cancer immunotherapy. New J Sci (2014) 0.85
Molecular targeted approaches for treatment of pancreatic cancer. Curr Pharm Des (2011) 0.85
Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells. World J Gastroenterol (2016) 0.85
Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother (2014) 0.84
Vaccine therapy for pancreatic cancer. Oncoimmunology (2013) 0.84
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. Oncoimmunology (2014) 0.84
MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. Immunol Endocr Metab Agents Med Chem (2012) 0.84
Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma. Oncotarget (2016) 0.84
Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget (2016) 0.84
Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine (2016) 0.83
Current progress in immunotherapy for pancreatic cancer. Cancer Lett (2015) 0.83
Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC Res Notes (2015) 0.83
Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res (2016) 0.83
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol (2017) 0.82
Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity. Cell Metab (2016) 0.82
Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clin Cancer Res (2015) 0.82
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med (2016) 0.81
Immune Therapy in GI Malignancies: A Review. J Clin Oncol (2015) 0.81
Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer. Cancer Immunol Immunother (2015) 0.81
Ipilimumab-induced colitis: experience from a tertiary referral center. Therap Adv Gastroenterol (2016) 0.80
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol Med (2015) 0.80
Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) (2015) 0.80
The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med (2014) 0.79
Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer. Semin Oncol (2014) 0.79
Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clin Cancer Res (2016) 0.79
Immune checkpoint therapy for pancreatic cancer. World J Gastroenterol (2016) 0.79
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity. Oncoimmunology (2015) 0.79
Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes (2015) 0.79
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. J Immunol (2016) 0.78
The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Commun Signal (2017) 0.78
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. Oncologist (2016) 0.78
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. Onco Targets Ther (2016) 0.78
Pancreatic cancer: chemotherapy and radiotherapy. N Am J Med Sci (2011) 0.78
CD86 gene variants and susceptibility to pancreatic cancer. J Cancer Res Clin Oncol (2012) 0.78
Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol (2012) 0.78
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene (2016) 0.78
Immunotherapy for pancreatic ductal adenocarcinoma: an overview of clinical trials. Chin J Cancer Res (2015) 0.78
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology (2015) 0.78
Tumor immunology: multidisciplinary science driving basic and clinical advances. Cancer Immunol Res (2013) 0.78
Role of immune cells in pancreatic cancer from bench to clinical application: An updated review. Medicine (Baltimore) (2016) 0.78
Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget (2016) 0.77
Viro-immune therapy: A new strategy for treatment of pancreatic cancer. World J Gastroenterol (2016) 0.77
Immunotherapy for pancreatic cancer. J Cancer Res Clin Oncol (2016) 0.77
Regramming myeloid responses to improve cancer immunotherapy. Oncoimmunology (2015) 0.77
PD-L1 Expression in Pancreatic Cancer. J Natl Cancer Inst (2017) 0.77
Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. Oncoimmunology (2014) 0.77
Immune suppression in tumors as a surmountable obstacle to clinical efficacy of cancer vaccines. Cancers (Basel) (2011) 0.77
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment. Cancers (Basel) (2016) 0.77
Current advances in immunotherapy for pancreatic cancer. Curr Probl Cancer (2013) 0.77
Pancreatic Cancer: Progress in Systemic Therapy. Gastrointest Tumors (2015) 0.77
Harnessing immune responses in the tumor microenvironment: all signals needed. Clin Cancer Res (2013) 0.77
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 12.88
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 7.76
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet (2011) 7.31
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood (2010) 7.25
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest (2005) 7.01
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol (2005) 6.95
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science (2014) 6.88
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med (2013) 6.01
Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell (2011) 5.63
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A (2005) 5.21
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Mutational inactivation of STAG2 causes aneuploidy in human cancer. Science (2011) 5.04
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol (2004) 4.73
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A (2004) 4.70
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res (2012) 4.56
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33